Search research articles
Contact Us
Filters
Showing results (11-20 of 29) with videos related to
Page
of 3
Sort By:
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
October 11, 2016
Acute ampakine treatment ameliorates age-related deficits in long-term potentiation
Daniel P Radin, Sheng Zhong, Richard Purcell, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 30, 2025
Is there a continued need for behavioral pharmacology in the discovery and development of medicines?
Jeffrey M Witkin, Jodi L Smith, Daniel P Radin
Clinical Pharmacology in Drug Development
|
September 20, 2024
Safety, Tolerability, and Pharmacokinetic Profile of the Low-Impact Ampakine CX1739 in Young Healthy Volunteers
Daniel P Radin, Rok Cerne, Jeffrey M Witkin, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 11, 2018
Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain
Daniel P Radin, Steven Johnson, Richard Purcell, et al.
Synapse (New York, N.Y.)
|
September 20, 2024
High Impact AMPAkines Induce a Gq-Protein Coupled Endoplasmic Calcium Release in Cortical Neurons: A Possible Mechanism for Explaining the Toxicity of High Impact AMPAkines
Daniel P Radin, Sheng Zhong, Rok Cerne, et al.
Biochemical Pharmacology
|
June 16, 2018
Tarps differentially affect the pharmacology of ampakines
Daniel P Radin, Yong-Xin Li, Gary Rogers, et al.
Biochemical Pharmacology
|
January 14, 2018
Stargazin differentially modulates ampakine gating kinetics and pharmacology
Daniel P Radin, Yong-Xin Li, Gary Rogers, et al.
European Journal of Pharmacology
|
August 9, 2025
Low-impact ampakine CX717 exhibits promising therapeutic profile in adults with ADHD - A phase 2A clinical trial
Daniel P Radin, Rok Cerne, Jodi L Smith, et al.
Journal of Psychiatric Research
|
April 17, 2025
Antipsychotic-like pharmacological profile of the low impact ampakine CX691 (farampator): Implications for the use of low impact ampakines in the treatment of schizophrenia
Daniel P Radin, Rok Cerne, Jodi L Smith, et al.
Anticancer Research
|
June 1, 2018
Ampakines Attenuate Staurosporine-induced Cell Death in Primary Cortical Neurons: Implications in the 'Chemo-Brain' Phenomenon
Daniel P Radin, Gary A Rogers, Kimberley E Hewitt, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 29) with videos related to
Sort By:
Page
of 3
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
October 11, 2016
Acute ampakine treatment ameliorates age-related deficits in long-term potentiation
Daniel P Radin, Sheng Zhong, Richard Purcell, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
April 30, 2025
Is there a continued need for behavioral pharmacology in the discovery and development of medicines?
Jeffrey M Witkin, Jodi L Smith, Daniel P Radin
Clinical Pharmacology in Drug Development
|
September 20, 2024
Safety, Tolerability, and Pharmacokinetic Profile of the Low-Impact Ampakine CX1739 in Young Healthy Volunteers
Daniel P Radin, Rok Cerne, Jeffrey M Witkin, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|
June 11, 2018
Effects of chronic systemic low-impact ampakine treatment on neurotrophin expression in rat brain
Daniel P Radin, Steven Johnson, Richard Purcell, et al.
Synapse (New York, N.Y.)
|
September 20, 2024
High Impact AMPAkines Induce a Gq-Protein Coupled Endoplasmic Calcium Release in Cortical Neurons: A Possible Mechanism for Explaining the Toxicity of High Impact AMPAkines
Daniel P Radin, Sheng Zhong, Rok Cerne, et al.
Biochemical Pharmacology
|
June 16, 2018
Tarps differentially affect the pharmacology of ampakines
Daniel P Radin, Yong-Xin Li, Gary Rogers, et al.
Biochemical Pharmacology
|
January 14, 2018
Stargazin differentially modulates ampakine gating kinetics and pharmacology
Daniel P Radin, Yong-Xin Li, Gary Rogers, et al.
European Journal of Pharmacology
|
August 9, 2025
Low-impact ampakine CX717 exhibits promising therapeutic profile in adults with ADHD - A phase 2A clinical trial
Daniel P Radin, Rok Cerne, Jodi L Smith, et al.
Journal of Psychiatric Research
|
April 17, 2025
Antipsychotic-like pharmacological profile of the low impact ampakine CX691 (farampator): Implications for the use of low impact ampakines in the treatment of schizophrenia
Daniel P Radin, Rok Cerne, Jodi L Smith, et al.
Anticancer Research
|
June 1, 2018
Ampakines Attenuate Staurosporine-induced Cell Death in Primary Cortical Neurons: Implications in the 'Chemo-Brain' Phenomenon
Daniel P Radin, Gary A Rogers, Kimberley E Hewitt, et al.
Page
of 3